What is ABS?
ABS Bio operates as a specialized biotechnology services provider, functioning as an essential extension of client laboratories. The company offers a comprehensive suite of services, including high-precision biospecimen sourcing, advanced cell culture techniques, secure biobanking, and dedicated laboratory support. By providing these foundational elements, ABS enables pharmaceutical firms to streamline their drug discovery pipelines and enhance the efficiency of preclinical research. Its market position is defined by its ability to maintain high-quality biological materials, which are indispensable for modern therapeutic development and rigorous scientific validation.
How much funding has ABS raised?
ABS has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in ABS
PPP
Public-Private Partnership
What's next for ABS?
Following this late-stage financing, ABS is well-positioned to scale its laboratory infrastructure and expand its biospecimen sourcing capabilities to meet the increasing demand for high-quality research materials. The strategic deployment of these funds will likely focus on enhancing technological integration within its biobanking facilities and potentially broadening its service portfolio to support emerging modalities in drug discovery. As the biotechnology sector continues to prioritize speed and accuracy in preclinical phases, ABS is poised to leverage its current momentum to capture a larger share of the outsourced research services market, ensuring that its clients maintain a competitive edge in the race to bring novel therapeutics to market.
See full ABS company page
